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MMPThis short review highlights some recent advances in matrix metalloproteinase inhibitor (MMPi) design and
development. Three distinct approaches to improved MMP inhibition are discussed: (1) the identiﬁcation
and investigation of novel zinc-binding groups (ZBGs), (2) the study of non-zinc-binding MMPi, and (3)
mechanism-based MMPi that form covalent adducts with the protein. Each of these strategies is discussed
and their respective advantages and remaining challenges are highlighted. The studies discussed here bode
well for the development of ever more selective, potent, and well-tolerated MMPi for treating several
important disease pathologies.
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Matrix metalloproteinases (MMPs) belong to a family of structur-
ally related Zn2+- and Ca2+-dependent endopeptidases that are
involved in the cleavage of extracellular matrix proteins. To date, over
20 MMPs have been identiﬁed and these enzymes can be loosely
classiﬁed based on their substrate speciﬁcity into collagenases,
gelatinases, stromelysins, membrane-type MMPs (MT-MMPs), and
others (Table 1) [1,2]. In normal physiology, MMPs are required for
various processes such as tissue remodeling, embryonic development,
angiogenesis, cell adhesion and proliferation, and wound healing.
MMPs are tightly regulated at both the transcriptional level and at the
protein activation level [2–4]. Expression of MMP mRNA is generally
low; however, transcript levels rise signiﬁcantly in response to
cytokines and growth factors during times of extracellular matrix
remodeling [3,5]. After MMPs are synthesized, they are secreted as
inactive zymogens and are found anchored to the cell surface or
within the extracellular matrix [3]. Activation of MMPs then occurs
through a variety of pathways, including proteolytic cleavage of the
propeptide domain by other MMPs or by furin-like serine proteases
[2,4]. MMP activity is constitutively regulated by endogenous protein
inhibitors called tissue inhibitors of metalloproteinases (TIMPs).
There are a total of four TIMPs (TIMP-1, -2, -3, and -4) and these
four protein inhibitors are able to control the proteolytic activity of all
MMPs [3,6–8].
Despite their physiological importance, misregulation of MMP
activity leads to the progression of various pathologies such as arthritis,ll rights reserved.multiple sclerosis, periodontal disease, and cancer [4,9,10]. For
example, in the case of cancer progression, the degradation of the
extracellular matrix has linked MMPs to tumor development through
metastasis and angiogenesis [9,11]. This has been shown with mouse
models of cancer using MMP-knockout mice or mice that overexpress
certain MMPs [11,12]. MMPs are not only expressed in tumor cells but
are also expressed in the surrounding stromal cells that have been
recruited to the neoplastic area, suggesting a broader role in cancer
than just their matrix degrading abilities [9,13,14]. In addition to
cancer, the expression of MMPs during the inﬂammatory response
induced by hypoxia/ischemia leads to the breakdown of the blood–
brain barrier (BBB) causing cell death and tissue damage [15]. The role
of MMPs in other inﬂammatory ailments such as arthritis [16] and
chronic obstructive pulmonary disease (COPD) [17,18] has further
veriﬁed the importance ofMMPs as a therapeutic target. Because of the
role of MMPs in these pathologies, MMP inhibitors (MMPi) have
emerged as an important area of drug development research.
By exploiting the presence of a metal ion and various substrate-
binding pockets, numerous synthetic MMPi have been designed and
developed over the past three decades [3,19–21]. The ﬁrst generation
of MMPi was small-molecule mimics of the natural peptide substrates
of MMPs that were combined with a hydroxamic acid zinc-binding
group (ZBG) to chelate the catalytic Zn2+ ion and inactivate the
protein [19]. These were potent, broad-spectrumMMPi that were able
to inhibit MMPs at low concentrations but without selectivity for one
MMP over another. Batimastat (1, Fig. 1, Table 2) is an example of one
of these early inhibitors.With the structure ofmoreMMPs determined
by crystallographic methods, second- and third-generation MMPi
were no longer limited to substrate-like compounds and new
inhibitors were designed with a variety of peptidomimetic and non-
peptidomimetic structures. These next-generation compounds were
Table 1
Classiﬁcation of MMPs.
MMP family MMP Enzyme name
Collagenases MMP-1 Collagenase-1, ﬁbroblast Collagenase
MMP-8 Collagenase-2, neutrophil Collagenase
MMP-13 Collagenase-3
MMP-18 Collagenase-4
Gelatinases MMP-2 Gelatinase A
MMP-9 Gelatinase B
Stromelysins MMP-3 Stromelysin-1, Proteoglycanase
MMP-10 Stromelysin-2
MMP-11 Stromelysin-3
Membrane-type MMPs MMP-14 MT1-MMP
MMP-15 MT2-MMP
MMP-16 MT3-MMP
MMP-17 MT4-MMP
MMP-24 MT5-MMP
MMP-25 MT6-MMP
Other MMP-7 Matrilysin-1, PUMP
MMP-12 Macrophage metalloelastase
MMP-19 RASI-1
MMP-20 Enamelysin
MMP-23 CA-MMP
MMP-26 Matrilysin-2, endometase
MMP-28 Epilysin
73J.A. Jacobsen et al. / Biochimica et Biophysica Acta 1803 (2010) 72–94designed to achieve greater selectivity, with an IC50 value against the
target MMP up to three orders of magnitude better (i.e., lower) than
the IC50 values against all other non-targetMMPs [22]. Prinomastat (2,
Table 2) is one such example of a second-generation inhibitor with
selectivity over MMP-1 and -7 [23]. These compounds were also
developed to have an improved therapeutic index, a parameter that
refers to the ratio between the concentration of inhibitor that causes
toxicity versus the concentration needed for in vivo efﬁcacy [24].
Even with improvements in the design of MMPi over the past few
decades, therapeutic inhibition of MMPs has been challenging as
evidenced by the fact that doxycycline, an antibiotic from the mid-
20th century, remains the only FDA-approved MMPi [2,3,19,25,26].
One limitation of many MMPi is their use triggers dose-limiting
musculoskeletal syndrome (MSS) as a side effect, which is character-
ized by joint stiffness, pain, inﬂammation, and tendinitis [9,25,27]. The
observed MSS has been attributed to the poor speciﬁcity and, hence,
broad inhibitory activity of early MMPi. In the past, MMP-1 inhibition
was thought to be the cause of these side effects and this led to the
development of MMP-1 sparing broad-spectrum inhibitors such as
Prinomastat (2). However, Prinomastat still caused MSS in clinical
trials [25]. Unfortunately, observations such as this, where preclinical
ﬁndings are not maintained in more advanced trials, have plagued the
ﬁeld of MMPi development [9]. In a separate study, it was found that
rats show signs of MSS when given broad-spectrum MMPi even
though MMP-1 is absent from the rodent genome [27]. Therefore, it
has been proposed that MSS may be caused by inhibition of anotherFig. 1. Diagram of Batimastat (1) showing zinc-binding mode, hydrogen bonding, and
distribution of substituents into the primed pockets [141].MMP, a combination of other MMPs, or by inhibition of other
metalloenzymes [9,25].
As mentioned above, the inhibition of MMPs involved in normal
matrix remodeling and of other metalloproteinases has been prob-
lematic [9,25,28]. For example, although the role of MMPs in the
progression of cancer is well established, MMPs are also known to
provide protective functions, such as repression of tumor angiogenesis
and inactivation of metastasis-mediating chemokines [11]. Another
factor that may have contributed to the problems of MMPi in clinical
trials is the temporal dosing of these compounds [9,19]. The beneﬁcial
effects of MMPi in most preclinical trials have focused on early stages
of cancer [9,19]. In contrast, most clinical trials administer MMPi in
advanced stages of cancer, where their efﬁcacy may be severely
compromised. Similarly, in the case of MMPi for the treatment of
stroke, evidence suggests that timing of drug administration is crucial
[29,30]. MMPi administered in the ﬁrst stages of stroke, immediately
after the onset of reperfusion, show reduced breakdown of the blood–
brain barrier (BBB) [30]. However, MMP inhibition at later stages
showed no signs of reduced infarct size and an increase of neurological
disorders due to interferencewith necessary tissue repairmediated by
MMPs [30]. Continuing efforts to resolve the role of different MMPs as
drug targets or anti-targets in various diseases, and the determination
of themost beneﬁcial stage of disease forMMPi administration, will be
crucial for the success of MMPi.
The shortcomings of the ﬁrst-generation MMPi prompted efforts
to develop more speciﬁc MMPi [19]. This review focuses on recent
developments in selective MMPi. Selectivity is a primary goal of MMPi
design to improve efﬁcacy and avoid unwanted side effects such as
MSS. While the clinically relevant goal for MMPi speciﬁcity may be to
achieve ~1000-fold difference in the relative afﬁnity between MMPs,
many current MMPi fall short of this goal. However, smaller
differences in MMP afﬁnity are discussed here to draw attention to
structural features of MMPi that may lead to improved designs. While
MMPi utilizing the traditional hydroxamic acid ZBG have shown
improvements in selectivity as evidenced by compounds such as
Prinomastat, the recurring side effects observed in clinical trials
highlight the need for improved MMPi selectivity and new
approaches to inhibition. In this article, a discussion of MMP structure,
including substrate-binding pockets, is presented to aid in the
discussion of recent MMPi developments. This is followed by an
examination of three innovative approaches to MMP inhibition: (1)
the use of potent ZBGs beyond the traditional hydroxamic acid group,
(2) non-zinc-binding inhibitors, and (3) mechanism-based inhibitors
that form covalent adducts with the protein. This short review only
captures part of the efforts in the area of MMPi development; more
comprehensive reviews of MMPi can be found in many excellent
compilations from the recent literature [3,19–21].
2. Challenges of MMP structure for MMPi selectivity
Achieving selective inhibition of MMPs has proved a challenging
goal because of the structural and functional similarity of most MMPs
[31]. MMPs are multi-domain proteins with highly conserved signal,
propeptide, and catalytic domains. The propeptide domain is
composed of about 80 residues and contains a conserved “cysteine
switch”motif PRCGXPD at the N-terminal, which binds to the catalytic
Zn2+ ion to block its activity. The sulfhydryl group of the cysteine
residue coordinates to the Zn2+ ion, thereby completing a 4-
coordinate, tetrahedral coordination sphere and maintaining enzyme
latency. MMP-2 and -9 contain three repeats of a ﬁbronectin-like
domain that are responsible for collagen recognition [32]. With the
exception of MMP-7, -23, and -26, a haemopexin-like C-terminal
domain is conserved among MMPs along with a hinge region of
variable length linking the haemopexin domain to the catalytic
domain [33,34]. In the case of MMP-23, the haemopexin repeat is
replaced by an immunoglobulin-like domain along with a unique
Table 2
Structures and IC50 values of MMPi with a variety of ZBGs.
ID Structure IC50 values (μM) unless otherwise noted Ref
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-11 MMP-12 MMP-13 MMP-14
1 Batimastat 3 nM 4 nM 20 nM 10 nM 10 nM [141]
2 Prinomastat 8.3 nM⁎ 0.05 nM⁎ 0.3 nM⁎ 54 nM⁎ 0.26 nM⁎ 0.03 nM⁎ 0.33 nM⁎ [23]
3 9 nM [45]
4 RS-104966 23 nM⁎ 0.13 nM⁎ [46]
5 N400 0.135 0.081 1.1 0.042 N7 0.0018 5 [68]
6 N6 0.351 N22 1.3 0.002 0.120 1.1 [71]
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7 0.147 0.00009 0.050 N1 0.0016 0.0067 0.0098 [63]
8 14 0.529 0.001 2.42 20.1 [65]
9 0.03 0.0098 1.7 0.475 0.003 17 [80]
10 3.3 0.032 0.057 [81]
11 N50 N120 80 N120 [81,82]
12 3.4 [82]
(continued on next page)
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13 58 200 1200 [82]
14 15 [84]
15 270 [84]
16 0.049⁎ 0.0011⁎ 0.470⁎ 0.04⁎ 0.00057⁎ 0.024⁎ [85]
17
0.005⁎
1.2⁎
0.04⁎
N100
0.0006⁎
0.7⁎
[87]
Top = R isomer
Bottom = S isomer
Table 2 (continued)
ID Structure IC50 values (μM) unless otherwise noted Ref
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-11 MMP-12 MMP-13 MMP-14
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18 0.160 0.02 0.150 1.4 0.0011 0.059 0.013 0.032 [88]
19 4.65⁎ 18.4⁎ 3.91⁎ 0.11⁎ 4.7⁎ 30.1⁎ [92]
20 N100 0.02 90 20 N100 [94]
21 N100 4 N100 N100 20 N100 N100 [95]
22 N500⁎ N/A 6⁎ N/A [97]
23 16 0.01 1.8 0.015 0.012 0.01 [98]
(continued on next page)
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24 0.14 0.14 0.22 0.00036 [105]
25 N50 N50 0.019 [76]
26 N50 0.92 0.56 N50 0.086 27.1 0.018 4.1 [75]
27 N1 0.005 0.056 0.0024 0.0025 [77]
28 N50 4.4 0.077 N50 0.248 32.3 0.085 6.6 [75]
Table 2 (continued)
ID Structure IC50 values (μM) unless otherwise noted Ref
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-11 MMP-12 MMP-13 MMP-14
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29 N50 16.5 41.7 N50 3.8 N50 1.2 16.5 [75]
30 N50 9.3 0.24 N50 0.064 N50 0.022 20.6 [75,76]
31 N50 7.6 N50 N50 5.0 N50 6.7 6.7 [75]
32 21% inhib.
at 100 μM
34% inhib.
at 100 μM
34% inhib.
at 100 μM
33% inhib.
at 100 μM
[109]
33 52% inhib.
at 50 μM
23 45% inhib.
at 50 μM
54% inhib.
at 50 μM
[109]
N/A=not active up to solubility limit.
⁎ =Ki value.
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domain and a cytoplasmic domain (MMP-14, -15, -16, and -24) or a
glycosylphosphatidylinositol sequence (MMP-17 and -25) as a
membrane anchor [6,36].
The conserved catalytic domain contains a catalytic Zn2+ ion, a
structural Zn2+ ion, and one to three structural Ca2+ ions required for
enzyme stability [4,31]. The catalytic Zn2+ ion is coordinated by three
histidine residues in a conserved HEXGHXXGXXHmotif and an axially
coordinated water molecule responsible for substrate proteolysis in
the active enzyme. The bound water molecule is additionally
hydrogen bonded to the carboxylate group of a glutamic acid residue
conserved in all MMPs [36]. The structural Zn2+ ion is bound by three
histidine residues and one aspartic acid residue [37]. In addition, the
catalytic domain contains a conserved methionine residue forming a
“Met-turn” that forms a hydrophobic base around the catalytic Zn2+
ion [38,39].
The catalytic Zn2+ ion is ﬂanked by “unprimed” (often referred to
as the ‘left-handed’ side) and “primed” (often referred to as the ‘right-
handed’ side) pockets designated S3, S2, and S1 and S1', S2', and S3',
respectively. Of these pockets, the S1' pocket varies the most among
the different MMPs in both the amino acid makeup and depth of the
pocket, whereas the shallower S2' and S3' pockets are more solvent
exposed [36]. MMPs can be generally classiﬁed based on the depth of
the S1' pocket into shallow, intermediate, and deep pocket MMPs
[36,40]. Shallow S1' pockets are found in MMP-1 and -7; MMP-2, -8,
and -9 have intermediate S1' pockets while MMP-3, -11, -12, -13, and
-14 have deep pockets [40–42]. Fig. 2 shows an example of each of
these S1' pockets. These differences have been exploited in attempts
to develop more selective MMPi with reasonable success. For
example, since MMP-3 can accept a very large substituent in the S1'
pocket (termed the P1' substituent), it can be targeted preferentially
over MMP-1 and -7 by using large aromatic groups [31]. However, the
use of bulky P1' substituents are merely a starting point for generating
selectivity against a few MMP family members, and many of these
inhibitors will also bind to intermediate and other deep pocket MMPs.
In the case of MMP-1 and -7, the S1' pocket is signiﬁcantly
occluded by Arg214 and Tyr214, respectively, resulting in a much
smaller pocket than that observed for other MMPs (Fig. 2). Successful
targeting to the S1' pockets of MMP-1 and -7 has generally used
smaller substituents such as leucine and isoleucine residues [43,44].
One such MMPi, 3 (Ro 31-4724, Fig. 3), is a potent inhibitor of MMP-1
[45]. Despite the shallow S1' pocket, there are severalMMPiwith large
P1' substituents that have been reported as potent MMP-1 inhibitors
[46,47]. For instance, the X-ray structure of MMP-1 complexed with
an MMPi possessing a diphenylether sulfone P1' substituent (4)
shows that the group extends deep into the S1' pocket, whereas the
peptide-based inhibitor does not (Fig. 3). This is achieved through an
induced ﬁt mechanism where the Arg214 residue is displaced by
inhibitor 4, creating a larger, more accommodating substrate pocket,
illustrating the importance of protein dynamics [46]. While MMP-7
also exhibits a smaller pocket due to occlusion by the analogous
Tyr214, an induced ﬁt conformational change has not been observed
for MMP-7 due to its shorter speciﬁcity loop creating a more rigid S1'
pocket [31,43].
Intermediate S1' pockets are observed in MMP-8 as well as in the
gelatinases MMP-2 and -9. Like MMP-1, MMP-8 belongs to the
collagenase family and shares similar substrate speciﬁcity [48]. To
accommodate the similar substrates with different pocket sizes,
MMP-8 has a larger opening to the S1' pocket, formed by the Leu160
and Ala161 residues, than observed for MMP-1 [36]. The catalytic
domains of MMP-2 and MMP-9 are highly homologous with
hydrophobic S1' pockets described as tunnels leading toward the
solvent [48,49]. The main structural differences between these two
enzymes are seen in residues 425–431 of MMP-9, which form a loop
in the S1' pocket that is not observed inMMP-2 [49]. Variability in size
and shape of the S1' pocket is due to the orientation of the residuesThr426 and Arg424 of MMP-2 and -9, respectively, located at the
bottom of the pocket [49]. Structures of MMP-9 co-crystallized with
different MMPi reveal that the Arg424 residue is highly ﬂexible and
with some MMPi can move into a position that blocks the S1' pocket
[50]. The occlusion by the Arg424 residue explains why some MMPi
with long P1' substituents do not inhibit MMP-9 as well as they inhibit
MMP-2 [50]. Due to the small differences in the S1' cavity, achieving
MMPi selectivity between the gelatinases MMP-2 and -9 is a
signiﬁcant challenge. One strategy to overcome these similarities is
to target additional pockets, including the S2 and S3' sites, where
variability between the gelatinases is more pronounced [36,51,52].
The S1' speciﬁcity pockets of MMP-3, -11, -12, -13, and -14 are
generally characterized as being large and open channels. In
comparison to other MMPs, the S1' loop of MMP-12 most closely
resembles that ofMMP-8 due to the presence of similar helical turns at
the bottom of the loop. However, theMMP-8 S1' pocket is closed off by
Arg214, whereas theMMP-12 pocket is open and extends to the solvent
surface [53]. Of the large pocketMMPs,MMP-12 is unique in that it can
accommodate binding of polar groups due to the Thr215 residuewithin
the S1' pocket where generally a Val or Ala residue is present in other
MMPs [48,53]. The large hydrophobic S1' pocket of MMP-13 has a
highly ﬂexible “S1' speciﬁcity loop” consisting of residues 245–253,
which has been shown to play a role in the binding of large P1'
substituents (vide infra) [46]. X-ray crystal structures show ﬂexibility
in the S1' loop, even in the presence of inhibitor binding, as evidenced
by missing electron density [41,46] and conﬁrmed by NMR spectros-
copy [54]. This pocket is highlighted by the Leu218 residue, which lies
to the side of the pocket creating an open space. In contrast, the
equivalent residue inMMP-1, Arg214, occludes the S1' pocket creating a
shallow binding pocket (vide supra).
The rough classiﬁcation of S1' speciﬁcity pockets into shallow,
intermediate, and deep pockets can aid in the development of
selective MMPi. However, the ﬂexibility of these pockets is important
to consider in the design of new compounds for targeting a given
MMP. One such example is MMP-1, which has a shallow speciﬁcity
pocket but can accommodate a diphenylether backbone in 4
commonly used to target intermediate and deep pocket MMPs.
Further structure analysis through X-ray crystallography and NMR
spectroscopy with inhibitors showing high selectivity will advance
this area of study.
3. ‘To bind zinc’: improvement of the ZBG in search of selective
MMPi
3.1. Early ZBGs
The design of MMPi has traditionally involved the use of a ZBG due
to the fact that the mechanism by whichMMPs cleave their substrates
directly involves the catalytic Zn2+ ion [55–57]. Upon binding of the
substrate, the zinc-bound water molecule attacks the substrate
carbonyl carbon, and the transfer of protons through a conserved
Glu residue to the amide nitrogen of the scissile bond results in
peptide cleavage [32,56,57]. Therefore, ZBGs in MMPi serve to
displace the zinc-bound water molecule and inactivate the enzyme
[19]. In addition, the ZBG acts as an anchor to lock the MMPi in the
active site and direct the backbone of the inhibitor into the target
substrate-binding pockets.
Early MMPi typically included use of one of several ZBGs, including
hydroxamic acids, carboxylates, thiols, and phosphonic acids [32]. Of
these, hydroxamic acids emerged as the preferred chelator for Zn2+
proteases due to their relative ease of synthesis and potent binding
[21,58–60]. Hydroxamic acids are monoanionic, bidentate chelators
that bind a variety of metal ions including Zn2+. A contributing factor
to the effectiveness of hydroxamates is the hydrogen bonding that
results between the heteroatoms of the ZBG and neighboring amino
acid residues that are conserved in all MMP active sites (Fig. 1).
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hydroxamic acid ZBG form hydrogen bonds with Ala and Glu residues,
respectively [19].
There has been some concern that the use of strong chelators, such
as hydroxamic acids, as ZBGs may preclude the development of
selective MMPi [19,20,22] due to undesired activity against off-target
metalloenzymes [25]. Despite this concern, several hydroxamate- and
carboxylate-based MMPi have been reported that show good
selectivity between different MMPs [61–65]. Additionally, a recent
study involving a macrophage cell model that monitored the activities
of several metalloenzymes including COX (heme iron dependent),
iNOS (non-heme iron dependent), TACE (zinc dependent), and MMPs
(zinc dependent) in the presence of various MMPi demonstrated that
the mere presence of a strong chelator as part of an inhibitor did not
inherently produce off-target metalloenzyme inhibition. Further-
more, this cell-based study showed that the off-target activity of a
given ZBG did not necessarily reﬂect the off-target activity of an
inhibitor containing the same ZBG [66].
Though potent inhibitors of MMPs, no hydroxamate-based MMPi
have been approved by the FDA. Many hydroxamate MMPi have
shown adverse musculoskeletal side effects in clinical trials presum-
ably caused by inhibition of other metalloproteins [21,25,26].
However, the generally poor oral bioavailability may be another
factor limiting the efﬁcacy of hydroxamic acids [2,19,25,26].
Furthermore, the hydroxamic acid functional group can be metab-
olized via dehydroxylation or it may be cleaved by exopeptidases to
release hydroxylamine [2,67]. This decreases the effective concen-
tration of the hydroxamate-based inhibitor and reduces its in vivo
potency.
Despite the aforementioned problems associated with hydroxamic
acids and the low potency of some carboxylate inhibitors, investiga-
tions continue on inhibitors containing both of these well-established
ZBGs. Recently, the main focus of research has been toward the
development of inhibitors with increased selectivity for a single MMP.
With this goal in mind, Wyeth published a series of biphenyl
sulfonamide carboxylate MMPi in 2005 that were designed for the
treatment of osteoarthritis and have remarkable selectivity for MMP-
13 [68–70]. In order to gain selectivity over MMP-2, which is highly
homologous to MMP-13, the P1' substituent was extended to take
advantage of the steric limitations of the shorter S1' loop of MMP-2. As
an example, compound 5 was a potent inhibitor of MMP-13
(IC50=1.8 nM) [68]; reasonably selective over MMP-2 (IC50=135
nM), MMP-3 (IC50=81 nM), and MMP-8 (IC50=42 nM); and highly
selective overMMP-1 (IC50N400 μM),MMP-7 (IC50=1.1 μM),MMP-9
(IC50N7 μM), and MMP-14 (IC50=5 μM) [68]. Compound 5 exhibits
100% bioavailability when dosed orally in rats at 20 mg/kg and
displays N50% inhibition of cartilage degradation in bovine cartilage
explant at 10 ng/mL [68].
Wyeth used this carboxylic acid scaffold as a starting point to
develop MMP-12 selective inhibitors for the treatment of COPD, in
which MMP-12 has been suggested to be a viable target for
therapeutic intervention [17,18]. In 2009, a series of inhibitors with
improved selectivity towards MMP-12 over MMP-13 were generated
by using a fused ring system [71]. Rather than increasing the length of
the P1' substituent, which would favor targeting MMP-13, it was
found that restricting the rotation of the biphenyl group favored
binding in the less ﬂexible MMP-12 S1' pocket. Inhibitor 6
demonstrated 60-fold selectivity for MMP-12 over MMP-13 and was
additionally reported to be selective over MMP-1, -3, -7, -9, and -14.
This inhibitor demonstrated in vivo efﬁcacy in an MMP-12-inducedFig. 2. Surface dot representations of the S1' speciﬁcity loops for MMP-7 (top, PDB code
1MMQ, shallow pocket), MMP-8 (middle, PDB code 1ZP5, intermediate pocket), and
MMP-3 (bottom, PDB code 1CIZ, deep pocket). The catalytic Zn2+ ion is represented as a
red sphere and the coordinating histidine residues are highlighted in green.
Fig. 3. Top. Ribbon drawing of MMP-1 (grey) complexed with the peptide-based inhibitor Ro 31-4724 (3) (green) showing occlusion of the S1' pocket by the arginine residue
(highlighted in blue) (PDB code 2TCL) [45]. Bottom. Ribbon drawing of MMP-1 (grey) complexed with the diphenylether sulfone inhibitor RS-104966 (4) (green) showing
displacement of the arginine residue (highlighted in blue), allowing for penetration of the inhibitor into the S1' pocket (PDB code 966C) [46]. The catalytic Zn2+ ion is represented as
a purple sphere in both views.
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6 for efﬁcacy in this model was 5 mg/kg two times a day.
Several selective hydroxamate inhibitors have been developed in
recent years. Rossello et al. have developed selective hydroxamic acid
inhibitors of MMP-2 as potent anti-angiogenic agents [63]. The
addition of alkyl substituents at the carbon atom adjacent to the
hydroxamic acid added lipophilic interactions with the S1 region of
the active site and improved the selectivity towards MMP-2. Inhibitor
7 represents one of the most selective MMP-2 inhibitors of this series
(N18-fold over MMP-8, -9, and -14 and N500-fold over MMP-1, -3,
and -7) [63]. Compound 7 was evaluated with a HUVEC (human
umbilical vein endothelial cells) chemoinvasion test and, at 1 μM, was
shown to reduce invasion across a Matrigel barrier to a basal level.
Another example of a selective hydroxamate inhibitor was a
compound designed with speciﬁcity towards MMP-3 for the treat-
ment of chronic non-healingwounds [65]. This compound (8) inhibits
MMP-3 with an IC50 of 1 nM and is N500-fold selective over MMP-1,
-2, -9, and -14. To achieve this selectivity, inhibitor 8 uses a reverse
sulfonamide group in which the sulfur and nitrogen have been
reversed in their placement with respect to the hydroxamic acid
binding group. This adds steric bulk near the hydroxamic acid, which
favors the large opening of the S1' pocket in MMP-3.
It is clear that hydroxamate and carboxylate ZBGs can be
developed into highly selective MMPi through careful consideration
of inhibitor backbones for targeting the substrate pockets of
individual MMPs. The inhibitors discussed have been devised bytaking advantage of a growing body of MMP crystallographic studies,
in combination with computer modeling, to attain greater selectivity
for the S1' pocket than their substrate analogue predecessors. In
particular, speciﬁc inhibitors for MMP-13 have been designed with
elongated backbones to probe deep into the S1' pocket, while rigid
backbones have been found to improve targeting of MMP-12. In
addition, emphasis on the opening of the S1' pocket, rather than the
interior of the pocket, has helped in the development of MMP-3
selective inhibitors. Though many inhibitors with hydroxamate or
carboxylate ZBGs continue to be investigated, a number of alternative
ZBGs have also been developed as a possible means to improving
selectivity, bioavailability, and pharmacokinetics.
Investigation of novel ZBGs has become an important aspect of
MMPi development. Fig. 4 displays a multitude of ZBGs (ZBG1–34)
that have been recently described in the literature. These include
oxygen, nitrogen, and sulfur donor–atom ligands and include
monodentate, bidentate, and tridentate chelators. This variety of
ZBGs displays a wide range of afﬁnities for the active site Zn2+ ion
and provides new opportunities to orient an inhibitor in the active
site. As mentioned before, early ZBGs include hydroxamic acids
(ZBG1), carboxylic acids (ZBG2), thiols, and phosphorus-based ZBGs.
For ease of reference, ZBGs that have some similarities to these early
zinc-binding groups are discussed ﬁrst. This is followed by an
examination of a newer class of nitrogen-based ZBGs. Finally, a
discussion of the heterocyclic bidentate chelators will be provided
[72–78].
Fig. 4. The structures of ZBGs used in MMPi. The most common ZBG is the hydroxamic acid group, represented here by acetohydroxamic acid (ZBG 1, AHA).
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In 2003, Auge et al. introduced hydrazide (ZBG3) and sulfonylhy-
drazide (ZBG4) analogues of the hydroxamate MMPi, Illomastat [79].
The hydrazide ZBG is isosteric to a hydroxamic acid and has the
potential for similar bidentate metal chelation (Fig. 5), though the
inhibitors obtained were considerably less potent than Illomastat. An
important advantage of the hydrazide and sulfonylhydrazide ZBGs is
that they can be derivatized to probe both the primed and unprimed
side pockets in the active site [80]. Sulfonylhydrazide 9 is a potent
inhibitor of MMP-1 (IC50=30 nM), MMP-2 (IC50=9.8 nM), and
MMP-9 (IC50=3 nM) [80]. Docking of 9 in MMP-2 and -9 shows that
the ZBG can make two hydrogen bonds with the peptide backbone
similar to hydroxamic acid inhibitors (Fig. 1). Computational
modeling also predicts that the backbone of this inhibitor targets
the S2, S1', and S2' pockets.
N-hydroxyurea (ZBG5) has also been investigated as an alternative
ZBG for MMPi because of its structural similarity to hydroxamic acids
and because of the improved oral bioavailability of N-hydroxyurea-derived 5-lipoxygenase inhibitors [2,67]. However, Michaelides et al.
observed a reduction in potency from the hydroxamic acid MMPi 10
to its N-hydroxyurea analogue, 11 [81]. A study by Campestre et al.
elucidated this loss in potency by comparison of the structurally
related inhibitors 11 and 12 [82]. Due to the ability of N-hydroxyureas
to adopt a trans N1-CO amide bond conformation, intramolecular
hydrogen bonding within the ZBG would preclude effective Zn2+
chelation [83]. It was proposed that methylation at N3 of 11 would
prevent intramolecular hydrogen bonding within the ZBG and would
therefore increase the ability of the inhibitor to chelate Zn2+. Though
the N-methylated inhibitor 13 was more than twice as potent against
MMP-2 as 11, the compound was still more than 50-fold less potent
than 12 against MMP-3. Crystal structures of 12 and 13 with MMP-
8 show that the N-hydroxyurea inhibitor binds the Zn2+ ion only
through the terminal hydroxyl group, while the hydroxamate
inhibitor chelates the Zn2+ ion in a bidentate fashion to form the
expected 5-membered ring (Fig. 5). The sp2 hybridization at N3 may
decrease the ﬂexibility of 13 relative to 12, leading to a binding
conformation that did not allow for chelation [82].
Fig. 5. Binding modes of several representative ZBGs to the Zn2+ ion.
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developed into MMPi in an attempt to target MMP-1 [84]. This ZBG
forms a 6-membered ring upon metal chelation as opposed to the 5-
membered ring of hydroxamic acid (Fig. 5). The thiocarbonyl squaric
acid full-length MMPi 14 was found to have an IC50 of 15 μM against
MMP-1, which was an 18-fold improvement over its carbonyl
precursor 15. The binding mode with squaric acid derivatives may
provide a means to uniquely position inhibitors into the substrate-
binding pockets that may prove fruitful in the design of selective
MMPi in the future. Further development of this ZBG is still necessary
to obtain more potent derivatives.
Hurst et al. reported a series of mercaptosulﬁde (ZBG8) inhibitors
in 2005 that target MMP-14 [85]. The role of MMP-14 in tumor-cell
invasion and metastasis has made it an attractive target for inhibition
[86]. Inhibitor 16, which uses a cyclic mercaptosulﬁde, was deter-
mined to be a competitive inhibitor of the catalytic domain of MMP-
14 with a Ki of 24 nM but was found to be more potent for MMP-2
(Ki=1.1 nM) and MMP-9 (Ki=0.57 nM) [85]. A structure–activity
relationship study indicated that the pentyl ring of 16 improves the
stability of the inhibitor as compared to linear mercaptosulphides,
which can be readily oxidized under air and therefore lose their
potency [85]. While the desired selectivity was not observed, the
utility of the mercaptosulphide inhibitors is that they can be modiﬁed
to target both the primed and unprimed side pockets of the MMP.
MMPi with phosphorus-based ZBGs have been investigated by
several laboratories. Much of this work is focused on the development
of α-biphenylsulfonylamino phosphonates, analogues of a known
group of MMPi that had been prepared with both carboxylate and
hydroxamate ZBGs [87–89]. MMP-8 was used as a model for
identifying the characteristic contacts of this inhibitor with residues
of the highly conserved MMP active sites. A crystal structure of the R-
enantiomer of 17 in MMP-8 showed that these ZBGs bind through two
phosphonate oxygen atoms in a distorted tetrahedral geometry [87].
It was found that compared to its enantiomer the R- stereoisomer of
17 demonstrates better hydrophobic interactions between the
isopropyl group of the inhibitor and the S1 pocket residues, shows
improved hydrogen bondingwith the sulfonamidemoiety, and allows
for better π stacking of the biphenyl backbone due to deeper S1'
insertion. Based on this series, Biasone et al. reported a potent
phosphonate inhibitor 18 that exhibits selectivity for MMP-8 over
MMP-1, -2, -3, -7, -9, -13, and -14 [88]. Selective MMP-8 inhibitors
could be useful in the treatment of acute liver disease and multiple
sclerosis [90,91].
Matziari et al. reported a series of phosphinate inhibitors that
show high selectivity for MMP-11, a presumed target for tumorigen-esis in breast cancer [92]. Compound 19 has a Ki=0.11 μM against
MMP-11, which is N30× more potent versus MMP-2, -8, -9, -13, and
-14 [92]. Much of the selectivity of the inhibitors is attributed to the
P1' interactions with the protein at the entrance to the S1' site. As
these inhibitors show speciﬁcity for MMP-11 over other deep pocket
MMPs, it is implied that the selectivity is not based solely on
exploitation of the S1' pocket size, as is common in other inhibitors,
but on other protein–inhibitor interactions. In particular, the
derivatives that showed the best selectivity were based on phenyl
rings that do not insert deeply into the S1' pocket. These results
indicate that targeting of MMPi toward the entrance of the S1' pocket
rather than deep in the pocket can provide a means to improve
selectivity. The use of phosphinic ZBGs may provide improved
metabolic stability of MMPi when compared to hydroxamates [92].
Another new phosphorus-based ZBG for MMPi is the carbamoyl
phosphonate ZBG (ZBG9). Instead of binding through two oxygen
atoms of the phosphonate, these ZBGs are proposed, based on
calculations, to bind Zn2+ through one oxygen of the phosphonate
and the oxygen of the carbonyl alpha to the phosphonate in order to
form a 5-member chelate ring that resembles the binding of
hydroxamic acid (Fig. 5) [93]. The amide bond of the carbamoyl
phosphonate may contribute to the improved activity of inhibitors
with this ZBG relative to α-ketophosphonate inhibitors because it
provides an extra hydrogen bond donor for protein interactions and
because the electron donating ability of the amide group allows for
stronger Zn2+ chelation [94]. The net negative charge on the ZBG
prevents cell penetration and restricts these inhibitors to the
extracellular space, contributing to their low toxicity [95]. Several
inhibitors based on these ZBGs are selective for MMP-2 and were
thereby evaluated in both in vitro and in vivo models of tumor
invasion and angiogenesis [94]. Speciﬁcally, compound 20 inhibits
MMP-2 with an IC50 of 20 nM yet inhibits MMP-1, -3, -8, and -9 with
IC50 values of 20 μM or greater [94]. The potency of 20 against MMP-
2 is remarkable considering its simplicity and very low molecular
weight. This inhibitor provides 40% inhibition at 50 μM in a
basement membrane cell invasion assay [94]. When dosed intraper-
itoneally at 50 mg/kg daily for three weeks in a murine model of
melanoma metastasis, 20 shows 55% inhibition of lung metastasis
formation [94].
More recently, the biological activity and pharmacokinetics of a
carbamoyl phosphonate inhibitor of MMP-2 and -9 (compound 21)
were evaluated more thoroughly [95]. This inhibitor spares MMP-1,
-3, -8, -12, and -13 while targeting MMP-2 and -9 with modest
potency at 4 μM and 20 μM, respectively. Compound 21 shows a dose-
dependent relationship with both inhibition of cell invasion in a
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murine melanoma model. Further, this inhibitor shows efﬁcacy with
both oral and intraperitoneal dosing and the minimum inhibitory
concentration of 21 is 12 ng/mL [95]. Compound 21 provides 60%
reduction in tumor growth and 90% reduction of metastasis at 50 mg/
kg in the more aggressive murine model based on orthotopic
implantation of human tumor prostate cells in immunodeﬁcient
mice [95]. Slow absorption and rapid elimination (t1/2 b 20 min for
intravenous administration) characterize the pharmacokinetics of this
inhibitor [95]. Prolonged absorption accounts for the sustained
efﬁcacy of this drug despite a low oral bioavailability of 0.3% [95].
These ZBGs offer the advantages that their inhibitors arewater soluble
at physiological pH and are not acutely toxic at the concentrations
used in themurinemodels (up to 500mg/kg for 21) [95]. The positive
pharmacokinetics and selectivity proﬁles displayed by the carbamoyl
phosphonates inhibitors discussed here indicate the potential
promise that this ZBG may have to develop clinically relevant
selective MMPi. However, obtaining more potent derivatives of
these carbamoyl phosphonate MMPi will be an important advance-
ment for this class of compounds.
3.3. Nitrogen-based ZBGs
In 2006, Jacobsen et al. introduced a well-known series of chelators
for use as nitrogen-based ZBGs (ZBG10–16) [96]. These ZBGs were
chosen due to their binding preference for late transitionmetals. ZBG10
(picolinic acid) binds Zn2+ via bidentate chelation through a carboxy-
late oxygen and the pyridine nitrogen as determined by the crystal
structure of ZBG10 in the bioinorganic model complex [(TpPh,Me)Zn
(ZBG10)] (TpPh,Me=hydrotris(3,5-phenylmethylpyrazolyl)borate).
Compounds ZBG10 and ZBG13–15 are all more than 100-fold more
potent for MMP-3 over acetohydroxamic acid (AHA, ZBG1) [96]. AHA
and maltol (ZBG24) both inhibit the activity of 5-lipoxygenase, an iron
enzyme, at 300 μM, while ZBG10-16 do not [96]. This supports the
hypothesis that use of nitrogen-based ZBGs may improve selectivity
towards Zn2+-dependent enzymes. Further synthesis of complete
MMPi with these ZBGs is needed to determine if these compounds
will be effective in producing selective MMPi.
Oxazolines of the type ZBG17 have been investigated as another
proposed nitrogen-based ZBG [97]. The oxazoline rings are modiﬁed
at the 4-position with a methylene hydroxyl group to allow for a
proposed binding mode via a 5-membered chelate ring between the
nitrogen atom of the oxazoline and the oxygen atom of the hydroxyl
group (Fig. 5). The relative position of the S1' pocket to the Zn2+ ion in
MMPs indicates that P1' substituents attached to the 2-position of the
oxazoline ring would be favorably directed toward the S1' pocket [97].
The best inhibitor reported based on this ZBG is compound 22, which
is a modest inhibitor of MMP-9 (Ki=6 μM) that does not inhibit
MMP-1, -2, or -12 up to 500 μM [97]. The bindingmode of this ZBG has
yet to be experimentally determined and more potent inhibitors need
to be developed to obtain better structure–activity relationships.
The most extensively studied class of MMPi with nitrogen-based
ZBGs are the pyrimidine-2,4,6-trione (and dionethione) inhibitors
(Fig. 4, ZBG18–19). In 2001, Hoffman-LaRoche published several
papers on a series of new MMPi with pyrimidine-2,4,6-trione ZBGs
[98–101]. The pyrimidine-2,4,6-trione group is a known feature in
many FDA-approved drugs (barbiturate class), and so its metabolic
disposition and bioavailability have been well studied [98]. Co-crystal
structures of pyrimidine-2,4,6-trione inhibitors in MMP-3 and -8
demonstrate that this ZBG binds to the Zn2+ using the N3 nitrogen
atom (Fig. 5) [99,101]. The carbonyl oxygen adjacent to the binding
nitrogen favors the enol form because it is stabilized by dual hydrogen
bonding between the enolate hydrogen and two oxygen atoms of a
neighboring glutamic acid residue [99,101]. The O6 and N1 atoms
around the ring produce further stabilization through hydrogen
bonding with the peptide backbone in the active site [99,101].Pyrimidine-2,4,6-trione MMPi were ﬁrst optimized for gelatinase
speciﬁcity to develop anticancer drugs [98,100]. New MMPi were
developed with improved potency for MMP-8, which was used as a
model for MMP-2 and -9 due to the structural homology of these
targets [98]. Derivitization at the 5-position of this ZBG provides
access to target the S1' and S2' subsites [98]. Parallel optimization of
the P1' and P2' substituents followed by merging of the optimized
inhibitor backbones led to the design of 23, which inhibits MMP-2, -8,
-9, and -14 with IC50 values ranging between 10 and 15 nM andMMP-
1 and -3 at micromolar concentrations [98]. In 2004, compound 23
was evaluated for anti-invasive, anti-tumorigenic, and anti-angiogen-
ic activity [102]. Compound 23 inhibits chemoinvasion by 85% at
concentrations as low as 10 nM and showed anti-cancer efﬁcacy in
several in vitro and in vivo models [102].
More recently, pyrimidine-2,4,6-trione MMPi have been opti-
mized to inhibit MMP-13 for the development of anti-osteoarthritis
drugs [103–106]. This work started with the development of
conformationally restricted spirobarbiturate inhibitors that mimicked
the binding geometry of a known MMP-13 hydroxamate inhibitor
[103]. Several spirobarbiturate inhibitors with P1' substituents based
on diphenylethers have Ki values on the order of 5 nM toward MMP-
13 [103]. Extension of the S1' binding diphenylether group with 5-
membered heterocycles yielded several inhibitors with N100-fold
potency for MMP-13 over MMP-14 [104]. Signiﬁcant selectivity for
MMP-13 over MMP-2, -8, and -12 was obtained with aryl oxazoline
derivatives of the diphenylether S1' binding moiety [105]. One such
inhibitor, compound 24, was evaluated in a hamster model to assess
its ability to inhibit MMP-13 in the synovial ﬂuid milieu [105].
Compound 24 was found to have an ED50 of about 1 mg/kg and
inhibited bovine cartilage degradation with an IC50 of 40 nM [105]. In
addition, no ﬁbroplasias were observed in a rat model of MSS at doses
up to 300 mg/kg twice per day [105]. However, spiropyrrolidine
barbiturate inhibitors with similar selectivity and in vivo activity
produce some rat ﬁbroplasias in this model [106].
3.4. Heterocyclic bidentate ZBGs
In 2004, Puerta et al. introduced a series of heterocyclic bidentate
chelators ZBG20–30 for development as alternative ZBGs in MMPi
[72]. These ZBGs were chosen because they have some features in
common with hydroxamic acids (5-member chelates, monoanionic)
but with potentially better biostability and tighter Zn2+ binding due
to ligand rigidity and, in some cases, the incorporation of sulfur donor
atoms. The binding modes of most of these compounds were veriﬁed
by characterization of an active site model system [(TpPh,Me)Zn(ZBG)]
[72,107,108]. In vitro assays showed these ZBGs all inhibited MMP-1,
-2, and -3 with greater potency than AHA: up to 15-fold improvement
for O,O chelators and up to 700-fold for O,S chelators [72,73]. Cell
viability assays show that the O,O chelators have low toxicity at
concentrations as high as 1mM,while the O,S chelators start to reduce
cell viability at concentrations above 100 μM [73]. In a cell invasion
assay, ZBG20 is the only O,O chelator that was able to inhibit cell
invasion at 1 mM, but several O,S chelators, ZBG26, ZBG27, ZBG28,
and ZBG30, are able to inhibit cell invasion at 100 μM [73].
Several of these ZBGs have been developed into complete MMPi
with good potency [75–78]. Relative to the ZBGs, the full-length
inhibitors are signiﬁcantly more potent and show some selectivity
between MMPs. Compound 25 is a full-length inhibitor based on
ZBG24 with an amide linkage to a terphenyl backbone that is N2500-
fold more potent for MMP-3 (IC50=19 nM) over MMP-1 and -2 [76].
Compound 26 is a nanomolar inhibitor of MMP-12 that is also potent
against MMP-2, -3, and -8 but is signiﬁcantly less effective against
MMP-1, -7, -9, and -13 [75]. Inhibitor 26 was tested in an ex vivo rat
heart model of ischemia and reperfusion. Hearts treated with 5 μM 26
were found to recover N80% of their original contractile function
versus 50% for untreated hearts [75].
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by ZBG20 that included expanded non-planar rings (ZBG31–34)
[78]. These ZBGs are 6-, 7-, and 8-membered heterocyclic chelators,
including 1-hydroxy-2-piperidinone, 1-hydroxyazepan-2-one, 1-
hydroxyazocan-2-one, and 1-hydroxy-1,4-diazepan-2-one. Because
these heterocycles are not unsaturated (nor aromatic) and hence
not planar, bond rotation is less restricted and this can result in out-
of-plane twisting of the chelating oxygen atoms. This decreases the
binding afﬁnity of these ZBGs as compared to ZBG20, and it was
found that, given the same backbone, ZBG20 provided the most
potent inhibitor. Following these ﬁndings, inhibitor 27, which uses
ZBG20, was developed and shown to have IC50 values ranging from
2.4 to 5.0 nM against MMP-2, -9, and -13 and was selective over
MMP-1 (IC50N1 μM) and moderately selective over MMP-3
(IC50=56 nM) [77]. Compound 27 exhibits an elimination half-life
of 47 h in rats dosed at 2 mg/kg intravenously and also demon-
strates a reduction in brain edema following ischemia–reperfusion
in a mouse transient mid-cerebral artery occlusion (tMCAO) model
[77].
In a systematic study, MMPi 26 and 28–31, each containing a
different ZBG connected to the same biphenyl backbone, were
examined against a series of MMPs [75]. These ﬁve MMPi have
different selectivity proﬁles, supporting the idea that the ZBG can
inﬂuence speciﬁcity. For example, the pyrone-based inhibitor 28 has
an IC50 value of 77 nM against MMP-3, while the IC50 value of the
hydroxypyridinone derivative 29 is 41.7 μM [75]. Similarly, compound
30 inhibitsMMP-3, -8, and -12with IC50 values ranging from 22 to 240
nM, while the IC50 values of 31 against all of these MMPs are above
5 μM [75]. Computer modeling of compounds 30 and 31 in the active
site of MMP-3 suggests that unfavorable steric interactions between
the ZBG in compound 31 and the protein may account for the
differences seen in the activity of these two MMPi [75]. This
systematic study, using a single common backbone with different
ZBGs, provides compelling evidence that even tight-binding ZBGs can
play a role in tuning MMPi selectivity.
Just as changes in the ZBG can generate differences in selectivity,
changes in the connectivity and point of attachment of the ZBG to
the backbone can also result in dramatic changes in potency and
selectivity. For example, MMPi 30 has an IC50 value of 240 nM
against MMP-3 [75,76]; however, the direct structural isomer of this
inhibitor, MMPi 32, shows only weak inhibition (~30%) at
concentrations as high as 100 μM [109]. This comparison shows
that two MMPi with the same chemical formula, ZBG, and backbone
can have vastly different activities based solely on the relative
positioning of the backbone on the ZBG. Furthermore, the analog of
32 that utilizes a sulfur donor atom (33) was also found to have
very different MMP inhibition proﬁles [109]. In a related compar-
ison using ZBG20, inhibitor 26 was found to be a semi-selective
inhibitor with nanomolar activity against MMP-3, -8, and -12 [75].
However, linking of a backbone to the 3-position in compound 27
(Fig. 7), rather than the 5-position (as in 26), of ZBG20 led to a
series of potent inhibitors against MMP-2, -9, and -13 [77,78]. In
both of the aforementioned examples, inhibitors have identical or
similar backbones and identical ZBGs but show dramatically
different MMP selectivity and potency based on the point of
attachment of the ZBG. Because the primary difference is the
position of the backbone on the heterocyclic ZBG, it is likely that a
change of the backbone orientation in the MMP active site is
responsible for the change in inhibitory behavior. This suggests
another means to exploit novel ZBGs for improved selectivity,
whereby the ZBG is used to preferentially position inhibitor
backbones toward different subsites to obtain optimal selectivity.
Such an approach can not be employed using traditional hydro-
xamic acid or carboxylic acid ZBGs. A better understanding of the
role of the ZBG in generating selectivity may provide another route
to obtaining selective inhibitors.4. ‘Or not to bind zinc’: non-zinc-binding MMPi
Over the last several years, numerous MMPi have been reported
that do not possess a ZBG and hence do not bind the catalytic Zn2+ ion
(Table 3, compounds 34–39) [41,110–116]. The rationale for this
strategy is that minimizing or eliminating the interaction with the
catalytic Zn2+ ion best achieves MMP selectivity, as the metal site is
the most conserved feature across all MMPs. Nearly all of these
inhibitors show impressive MMP-13 selectivity and bind deep within
the S1' pocket to induce a speciﬁc protein conformation. Several
inhibitors from this class show promise in the treatment of
osteoarthritis in animal models [41,110].
Certain structural features are thematic across this class of
inhibitors. All tend to be fairly long molecules with linked ring
structures that are aromatic or otherwise planar. While the inhibitors
are generally hydrophobic, carbonyl oxygen atoms and N–H groups
offer opportunities for hydrogen bonding interactions with the S1'
pocket. Some non-zinc-binding MMPi have hydrophilic ends that
have been shown, based on crystallographic data and molecular
docking studies, to extrude into solvent-exposed areas from the active
site [110,111,113].
Most non-zinc-binding inhibitors have been characterized by
crystal structures with MMP-8, -12, or -13 [41,111–113,116]. These
structures conﬁrm that these MMPi have no signiﬁcant interactions
with the Zn2+ ion, with the closest ligand–zinc distances on the order
of ~5 Å [111,112]. It is of note that while the inhibitors have been
crystallized with a number of MMPs, all of the compounds are
generally selective for MMP-13 (see Table 3). While each of the
crystallized MMPi is structurally distinct, many of their protein
binding interactions seem to be conserved. Backbone hydrogen
bonds, hydrophobic aromatic interactions, and protein ﬂexibility are
the key features of these inhibitor–protein complexes. The interac-
tions of a representative inhibitor 34with MMP-13 are highlighted in
Fig. 6 [41]. The phenyl group of the benzyl ester of 34 is aligned almost
in parallel with the plane of His201. The carbonyl oxygen of the ester is
twisted to allow for hydrogen bonding with the amide backbone of
Thr224. The other two carbonyl oxygen atoms form hydrogen bonds to
the amide backbones of Thr226 and Met232. Both faces of the terminal
benzyl group are involved in aromatic edge–face interactions with the
side chains of Tyr225 and Phe231. Gly227 is rotated to a main chain
conformation, which opens the S1' pocket to accommodate the
inhibitor.
Crystallization studies of these non-zinc-binding MMPi often
involve co-crystallization with AHA (ZBG1) to prevent autolysis.
Morales et al. showed that AHA is not displaced by the non-zinc-
binding inhibitors when crystallized in MMP-12 (35 and 36) [111].
A similar observation was made by Johnson et al. with inhibitors 34
and 37 in MMP-13 (Fig. 6) [41]. It is important to consider that the
presence of AHA in the crystallization conditions may predispose
the positioning of the inhibitor to a non-zinc-binding orientation
that is different than would be observed in the absence of AHA.
However, other crystal structures of non-zinc-binding MMPi do
show similar hydrogen bonding interactions with the inhibitor and
protein backbone; one example is compound 38 co-crystallized with
MMP-12 [112].
The kinetics of several non-zinc-binding MMPi show a non-
competitive mechanism of inhibition. Gooljarsingh et al. recently
described the kinetics of a pyrimidine dicarboxamide inhibitor 39 and
compared it to the kinetics of AHA (ZBG1) and a hydroxamate MMPi
[115]. Through dual inhibition studies, it was found that AHA and the
hydroxamate-based MMPi act as competitive inhibitors, while the
non-zinc-binding 39 was non-competitive. Further, when the hydro-
xamates were tested in concert with 39, it was found that AHA led to
synergistic potency with 39, while the bulky hydroxamate was
antagonistic. Modeling studies showed overlap between the binding
space of the large hydroxamate and 39 but showed independent
Table 3
Structures and IC50 values (μM) of non-zinc-binding MMPi.
ID Structure IC50 value (μM) Ref.
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-12 MMP-13 MMP-14
34 N100 N100 N100 N100 N100 N100 N100 0.03 N100 [41]
35 N100 0.39 1.7 0.98 1.4 0.014 0.27 [111]
36 N100 6.6 N100 5.1 N100 24 4.9 [111]
37 N30 N30 N30 N30 N100 N100 N100 0.00067 N30 [41]
38 NI NI NI NI NI NI NI 6.6 NI [112]
39 0.072 [112]
NI=no inhibition at concentrations up to 100 μM.
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experimental ﬁndings. Johnson et al. also found that a non-
competitive mechanism of inhibition best described the kinetics of
34 [41]. The crystal structure of this inhibitor with MMP-13 shows
that it binds deep in the S1' site where there is no overlap with the
natural substrate-binding space [41].
As stated earlier, most of the non-zinc-binding MMPi show
remarkable selectivity for MMP-13 [41,110–112]. Among the best is
37, which inhibits MMP-13 with an IC50 value of 0.67 nM but does not
appreciably inhibit MMP-1, -2, -3, -7, -8, -9, -12, -13, -14, or -17 up to
100 μM. The source of the selectivity for 37 has been attributed to
speciﬁc S1' binding interactions observed in structures of similar
compounds (Fig. 6) and to the general differences in the shape and
size of S1' pockets across the various MMPs. Selectivity of 37 over
MMP-1, -2, -7, -8, and -9 is due to the shorter S1' speciﬁcity pockets,
which may not be able to accommodate the especially long P1'
substituents of 37. Additionally, as discussed earlier, the MMP-13 S1'
pocket displays substantial ﬂexibility. While many crystal structureswith zinc-binding inhibitors show disorder in the S1' region, it is
notable that in several of the structures with non-zinc-binding
inhibitors, the S1' pockets are crystallographically well-deﬁned
[41,112]. Binding of these inhibitors may rigidify the enzyme active
site into a speciﬁc conformation that is less productive for substrate
binding. The ﬂexibility of MMP-13, relative to other MMPs, may allow
for this favorable conformation where it is not accessible in other
MMPs. Speciﬁcally, certain glycine residues (Gly227 and Gly248 with 34
and 38 inhibitors, respectively) in MMP-13 rotate relative to the main
chain conformation in the inhibitor-bound protein structure [41,112].
With each of these rotations, the S1' pocket opens to an exosite, which
extends the pocket length and allows the protein to accommodate the
long inhibitors. Inhibitor binding prevents the glycine residue from
rotating back to a side chain conformation and thereby rigidiﬁes the
pocket structure. This would explain the conformational order seen in
the S1' site of these inhibitor complex structures of MMP-13. It may
also account for the high afﬁnity of these inhibitors for MMP-13.
Because these glycine residues are not conserved in other MMPs and
Fig. 6. Left. Ribbon structure of MMP-13 (grey) co-crystallized with the non-zinc-binding inhibitor, 34 (highlighted in green), and acetohydroxamic acid (highlighted in red) (PDB
code 2OW9) [41]. Right. Magniﬁed view of 34 in S1' speciﬁcity loop highlighting the hydrogen-bonded residues Thr224 (cyan), Thr226 (orange), and Met232 (yellow). The catalytic
Zn2+ ion is represented as a purple sphere in both views.
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other residues, decreased afﬁnity for other MMPs would be expected.
Similar induced conformations have been observed in the crystal
structures of MMP-8 with non-zinc-binding inhibitors [116].
As most of these non-zinc-binding MMPi are potent and selective,
derivatives have aimed to improve their drug-like properties
[110,113]. The hydrophobicity of these inhibitors is critical in
maintaining productive protein–inhibitor interactions that result in
high potency; however, it also results in poor water solubility. In order
to improve the solubility with minimal effect on potency, derivatives
have been explored to speciﬁcally modify the solvent-exposed
portions of the molecule while maintaining the hydrophobic core
structures. Dublanchet et al. found that carboxylic acids positioned
toward solvent-exposed parts of the molecule help to signiﬁcantly
solubilize MMPi that are otherwise poorly soluble [113].
Preclinical studies with 37 in models of osteoarthritis have shown
encouraging results [41]. Compound 37was found to have an efﬁcacy at
doses as low as 0.1mg/kg in anMMP-13-induced rat model of cartilage
knee joint damage. This model was used to show that 37 had in vivo
activity in a relevant disease system and to establish the dosing efﬁcacy
todetermine the viablemodes of drug administration. Oral dosing twice
daily at 30mg/kgof37 resulted in a 68% reduction in the cartilage legion
area of tibial plateaus in rats with surgically induced cartilage knee
damage. The rat joints were subsequently examined for evidence of
ﬁbroplasias and expanded inner synovial lining, which are indicative of
MSS. The ﬁbroplasias were absent in all vehicle and rats dosed with
compound 37 but present in all rats dosed with broad-spectrumMMPi.
Inhibitors of this kind, with such a high degree of selectivity, may
become an important solution to the toxic side effects associated with
broad-spectrum MMP inhibition. However, this strategy is limited by
the design challenges posed in obtaining such highly selective MMPi.
Additionally, it is often unknown how relevant certain MMPs are to
disease processes; identiﬁcation of diseases that respond signiﬁcantly to
inhibition of only one MMP may be challenging.
These non-zinc-binding inhibitors are remarkable primarily
because of their high selectivity. It is clear that a major reason for
the selectivity of 34 and 38 is their ability to induce a unique
conformation in the S1' speciﬁcity loop of MMP-13 that is not
accessible in other MMPs [41,112]. It is not yet clear if the observed
selectivity of these inhibitors actually relies on the fact that there is no
ZBG present. A comparison between one of these inhibitors and an
inhibitor that can both induce a conformational change in the MMP-
13 S1' pocket and chelate the active site Zn2+ ion would provide
signiﬁcant insight on this topic.5. Mechanism-based MMPi
In 2000, Mobashery and coworkers introduced SB-3CT (Table 4,
40) as the ﬁrst mechanism-based inhibitor of MMPs (Fig. 7) [117].
This inhibitor binds in the active site and forms a covalent bond with
the protein upon activation by Zn2+ coordination. The formation of
the covalent bond impedes inhibitor dissociation relative to tradi-
tional, chelating, competitive inhibitors. This ensures that the rate of
catalytic turnover is reduced, and therefore, less inhibitor is needed to
saturate the enzyme active sites. Compound 40 is a selective inhibitor
of MMP-2 and -9 and shows promise in pre-clinical studies as an
inhibitor of bone metastasis in prostate cancer and in the prevention
of damage caused by cerebral ischemia.
The structure of 40 is relatively simple, which is reﬂected by its low
molecular weight [117]. The backbone of 40 is a diphenylether, a well-
known S1' binding moiety that is present in many MMPi
[77,78,103,118–124]. The inhibitor coordinates the Zn2+ via the
sulfur of its thiirane ring. No crystallographic data of inhibitor binding
in the protein active site is available; however, monodentate
coordination to generate a tetrahedral Zn2+ center was conﬁrmed
by X-ray absorption spectroscopy [125]. The backbone and thiirane
ring are connected by a sulfone group and a methylene linker. The
oxygen atoms of the sulfone are proposed to form hydrogen bonds
with amide hydrogen atoms from the backbone of two active site
residues: Leu191 and Ala192 (numbering for MMP-2) [117]. This
hydrogen bonding has been seen in other sulfone inhibitors [87,89].
Inhibitors with two or three methylene groups between the sulfone
and the thiirane ring are inactive [117]. These inhibitors do not
properly position the thiirane ring within the Zn2+ coordination
sphere.
The mechanism of inhibition of 40 is similar to that of a “suicide
substrate” in which a functional group is activated, leading to
covalent modiﬁcation of the enzyme active site [117,126]. It is
proposed that the thiirane group of 40 activates upon Zn2+
coordination (Fig. 7), which results in ring opening via a nucleophilic
attack from an active site glutamic acid residue (Glu404) forming a
covalent ester bond between the carbon from the thiirane ring
and Glu404 [117]. This bond tethers the inhibitor in the active site,
thereby resulting in low inhibitor dissociation. Upon inhibitor bind-
ing, the Zn–S bondwith 40 is at a distance of 2.22 Å, comparable to the
Zn–S bond with cysteine (2.24 Å) of the pro-enzyme [125,127]. This
indicates that a thiolate group strongly coordinates Zn2+ in the
inhibited complex and supports the proposed mechanism of inhibitor
activation [125].
Table 4
Structures and Ki (μM) values of mechanism-based MMPi.
ID Structure Ki value (μM) Ref.
MMP-1 MMP-2 MMP-3 MMP-7 MMP-9 MMP-14
40 SB-3CT 73 0.028 4 67 0.400 0.110 [137]
41 NI 25 NI NI 186 [117]
42 NI 0.046 10 NI 0.100 0.21 [131]
43 128 0.006 2.2 31 0.16 0.09 [137]
44 [137]
45 140 0.023 0.600 18.2 0.005 0.145 [139]
NI=no inhibition at concentrations up to 60 or 130–330 μM (see refs. [117,131] for details).
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-9, with a time scale for the establishment of equilibrium between the
enzyme and inhibitor and the enzyme–inhibitor complex on the order
of seconds to minutes [126]. Slow-binding inhibition is characterized
by slow dissociation rates (koff), though the binding rate (kon) can be
slow or fast [126]. The rate of dissociation of 40 fromMMP-2 and -9 is
on the order of 10−4 s−1. Progress curves, which display enzyme
activity over time of MMP-2, -9, and -3 with 40, are non-linear [117].
The curves show that the initial enzyme rate is not maintained and is
instead reduced to a new “steady-state rate” of MMP activity. This
indicates a slow-bindingmechanism of inhibition and is characteristic
of an enzymewith an inhibitor that resists dissociation. The binding of
40 in MMPs is nearly irreversible. Following 95% inhibition, MMP-2
regains 50% activity only after 3 days with dialysis, even though the
recovery time calculated based on the koff value is 6 min (without
dialysis) [117]. The fact that there is any recovery indicates the
inhibitor exhibits some reversibility. This can be attributed to the
lability (due to slow hydrolysis) of the ester bond that is formed upon
inhibitor activation and binding [117]. The small degree of revers-
ibility of 40 is what distinguishes it from a true suicide inhibitor,
which operates strictly by an irreversible mechanism [117,126].
The selectivity of 40 is based on the differences in binding kinetics
for variousMMPs. As demonstrated by the non-linear progress curves,
inhibition increases over time, as slow-binding inhibitors do not
dissociate readily from the active site. 40 has nanomolar Ki values forMMP-2 (28 nM), MMP-9 (400 nM), andMMP-14 (110 nM) [128,129].
However, 40 inhibits MMP-2 and -9 via a slow-binding mechanism
while inhibition of MMP-14 occurs through competitive inhibition.
This difference in kinetics has been proposed as the rationale for the
observed selectivity that 40 shows for MMP-2 and -9 over MMP-14
[129].
Several structural variations of the thiirane ring have been
explored in an attempt to better understand the activity of 40. The
effect of the stereochemistry of the thiirane ring was examined
through synthesis and evaluation of the enantiomers of 40. Surpris-
ingly, both R- and S- stereoisomers are active MMPi [128]. However,
derivatives containing an epoxide ring such as 41 instead of thiirane
are inactive against all MMPs tested even at high micromolar
concentrations [117,130]. Several inhibitors were made in which the
thiirane ring of 40 was changed to a dithiol, such as compound 42
[131]. In contrast to 40, it was found that the carbon length between
the sulfone and the thiols could be varied without signiﬁcantly
reducing the activity of the inhibitors.
In preclinical studies, 40 has yielded anti-cancer results for both a
T-cell lymphoma model and a prostate cancer model [132–134]. In
vitro Matrigel tests showed that 1 μM of 40 reduces the invasion
ability of BMEC-1 tumor cells by 30% as compared to the vehicle
control [133]. Compound 40 was tested in a mouse model of T-cell
lymphoma with a dosing range of 5–50 mg/kg/d and was found to
promote a dose-dependent reduction in the number of liver
Fig. 7. Scheme for the activity of mechanism-based MMPi (SB-3CT, 40).
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and signiﬁcantly reduces the colony size of the metastases, while the
broad-spectrum inhibitor Batimastat (1) led to increased metastasis
in the same tumor model [132,135]. Additionally, in vitro tests show
that the inhibitor does not affect cell growth or viability up to
12.5 μM[132]. Promising resultswith 40 in a bonemetastasismodel of
prostate cancer show reduced tumor growth and angiogenesis [133].
The use of 40 in a murine stroke model provides signiﬁcant
neuronal protection [136]. Infarct volume is decreased to 30% of the
control in mice treated with 40 either prior to or 2 h following
ischemia induced by right middle cerebral artery occlusion. Admin-
istration of 40 is protective up to 6 h after the ischemic event in mice.
Neurological behavioral scores evaluated 24 h after reperfusion show
that 40-treatedmice exhibit signiﬁcant improvements as compared to
the control mice, correlating to the observed infarct volumes.
Though it has signiﬁcant in vivo activity, 40 undergoes rapid
metabolism in mice [137]. This leads to low systemic exposure and
suggests that a metabolite of the parent compound may be
responsible for the in vivo activity. Eight metabolites of 40 were
identiﬁed in the plasma and urine of mice following intraperitoneal
administration of the inhibitor, two of which are primary metabolites
(Table 4, 43 and 44) [137,138]. Metabolite 43 is a more potent
inhibitor of MMP-2, -3, -7, -9, and -14 than 40. Additionally, it
demonstrates slow-binding kinetics with MMP-2, -9, and -14 [137].
Analysis of the metabolites led to the design of derivatives that have
better in vivo stability and provide longer systemic exposure [139].
Computational modeling and analysis of major metabolites of 40
indicates that the terminal aromatic ring would be best modiﬁed at
the 4-position with a sulfonate moiety to block one of the major
metabolic pathways of the original inhibitor [139]. Inhibitor 45 is a
slow-binding inhibitor of MMP-2 and -9 but a competitive inhibitor of
other MMPs. Interestingly, the inhibitor is more potent for MMP-9
than MMP-2 (Ki=5 nM and 23 nM, respectively). The metabolites of45 are 75% more stable than those of 40, resulting in signiﬁcantly
higher systemic exposure.
SB-3CT and its successors show great clinical promise. The use of
mechanism-based, slow-binding inhibitors may provide a new
approach to gain selectivity in MMPi design. Other types of covalent
modiﬁcation in the active site may lead to new patterns of selectivity.
It will be interesting to see if this class of inhibitors can be expanded to
explore selectivity toward other MMPs.
6. Outlook
Improvements in the design of selective MMPi have been realized
over the last several years. In addition, studies suggest that semi-
selective MMPi may fare better clinically than their broad-spectrum
predecessors; however, this may require the development of
inhibitors with very narrow windows of activity. Therefore, it is
necessary that creative new approaches to address the challenges of
obtaining a high degree of MMP selectivity be uncovered. This review
has focused on three such approaches, namely, MMPi based on
alternative ZBGs, non-zinc-binding MMPi, and mechanism-based
MMPi. Each of these approaches has potential as a distinct means to
discover MMPi with improved selectivity and biological properties.
Awide array of novel ZBGs has been introduced in recent years that
has greatly expanded the number of chemical ‘platforms’ from which
potent MMPi can be developed. Like hydroxamic acids, inhibitors
based on these new ZBGs exhibit kinetics of competitive inhibition. In
some cases, novel ZBGs allow for incorporation of multiple backbones
targeting both sides of the active site (so-called double-handed
inhibitors), which has great potential for attaining MMPi selectivity
across a number of MMPs.While selectiveMMPi have been developed
with new ZBGs, there continue to be valid concerns that the use of
strong metal chelators may preclude the development of highly
selective MMPi due to the highly conserved nature of the Zn2+ active
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including demonstrations of signiﬁcant enhancements in MMP
selectivity as well as selectivity over other metalloenzymes. In
addition, more studies on the bioavailability and pharmacokinetics
of these MMPi are required to determine if improvements in these
properties are indeed conferred by these compounds.
In contrast to the use of novel ZBGs, substantial success has been
achieved with the fundamentally opposite approach, that is, MMPi
that do not possess a ZBG at all. This method has proven to be an
excellent route for development of selective MMPi for deep pocket
MMPs, speciﬁcally MMP-13. Unlike inhibitors that employ Zn2+
chelation, these compounds display a non-competitive mechanism of
inhibition. An advantage of non-zinc-binding MMPi is a potential
reduction in non-speciﬁc, off-target metalloenzyme inhibition. To
date, the use of non-zinc-binding MMPi relies on the intrinsic
ﬂexibility of the S1' speciﬁcity loop, which is why this method has
proven most useful for the development of MMP-13 selective
inhibitors. The major challenge for these MMPi is whether selective
inhibition of other MMPs will be forthcoming.
Another innovative approach to improved MMPi are mechanism-
based inhibitors, in which the inhibitor binds in the active site and is
activated to form a covalent adduct with the protein. These MMPi
exhibit slow-binding inhibition characterized by slow dissociation
rates and a reduced steady-state rate of MMP activity. This strategy
relies on the nucleophilic attack from an active site glutamic acid
residue that is conserved in all MMPs. The conserved nature of the
glutamic acid suggests that this approach should be widely applicable
across many different MMPs. It is important to note that metallopro-
teinases other than MMPs also have active site residues that may be
susceptible to these inhibitors [43,140]. Demonstration of new MMP
selectivity in these mechanism-based MMPi and additional informa-
tion on their in vivo activity remain importantmilestones for this class
of compounds.
As this review highlights some of the recent approaches in MMP
inhibition, it is evident that much work remains to develop these
compounds into clinically successful MMPi. Each new approach has its
unique advantages as well as its speciﬁc challenges that remain to be
overcome. It is imperative that future studies on MMPi should include
assessments against a wide battery of MMPs and other metallopro-
teinases in order to verify target speciﬁcity. With so many inventive
approaches in the development of next-generation MMPi, it is clear
that the opportunities for discovering clinically relevant compounds
remain strong.
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